ArticleBiosensors2026
Label-Free Refractive-Index-Based Detection of Breast, Leukemia, and Prostate Cancer Cells Using a Tetra-Core PCF SPR Biosensor.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In this research, a high-performance plasmonic refractive index (RI) biosensor based on an external metal deposition (EMD) technique and photonic crystal fiber (PCF) platform for potential cancer detection is presented, investigated, and linked with real-time cancer cells. Variations in the RI of biological fluids are closely associated with pathological conditions, including cancer, due to changes in cellular composition and biomolecular concentration. The proposed tetra-core PCF-SPR biosensor operates within the biologically relevant RI range of 1.33-1.37, enabling the detection of subtle RI variations corresponding to various cancerous cells. The sensing mechanism of the proposed sensor is based on surface plasmon resonance (SPR) and analyzed using coupled mode light theory for both x- and y- polarized modes. Key sensing performance parameters, including confinement loss (CL), wavelength sensitivity (WS), amplitude sensitivity (AS), sensor resolution (SR), and figure of merit (FOM) are systematically evaluated. The biosensor reports a WS of 9769 and 9069 nm/RIU for x-pol. and y-pol., respectively, AS of 623.182 and 645.087 RIU-1 for x-pol. and y-pol. respectively, SR in the order of 10-5 RIU, coefficient of determination (R2) of 0.97 and 0.96, and FOM of 60.17 and 53.01 RIU-1 for x-pol. and y-pol., respectively. Thus, the proposed PCF-SPR biosensor exhibits a dynamic range of 0.04 RIU. The sensing results demonstrate high sensitivity and strong resonance characteristics, indicating the capability of the proposed biosensor for label-free and non-invasive detection of cancer-associated RI changes in biological fluids. Thus, the presented biosensor offers a promising approach for the highly sensitive label-free detection of early-stage cancer cells by photonics sensing application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.